Navigation Links
New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
Date:9/21/2011

RIDGEFIELD, CT, Sept. 21, 2011 /PRNewswire/ -- Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine (NEJM). IPF is a progressive and severely debilitating lung disease with a high mortality rate, for which there are no approved treatments in the United States.

(Logo: http://photos.prnewswire.com/prnh/20110921/NY71310LOGO)

In the study, known as TOMORROW (To Improve Pulmonary Fibrosis with BIBF 1120), patients treated with 150 mg of BIBF 1120 twice daily demonstrated a 68 percent reduction in the rate of forced vital capacity (FVC) decline compared to placebo. FVC is the volume of air that is expelled into a spirometer following maximum inhalation. FVC, which is a test that measures lung function, is a part of the examinations conducted in IPF patients and is scientifically accepted for assessment of IPF treatment effects. Patients treated with 150 mg of BIBF 1120 twice daily also had a lower incidence of acute exacerbations, defined as sudden deterioration of clinical status, compared with placebo. Acute exacerbations are associated with rapid disease progression, severe abrupt decline in FVC and high mortality.

In addition, treatment with 150 mg of BIBF 1120 twice daily resulted in a small decrease in impairment of quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ). SGRQ scores measure the impact of quality of life, with higher scores – as well as increasing scores – signaling greater impairment. In contrast, increased impairment was reported among patients receiving placebo.

Gastrointestinal symptoms and liver transaminase increases were more freq
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
2. Studying Fluid Overflow in Patients With Devices
3. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
4. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
5. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
6. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
7. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
10. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
(Date:1/22/2015)... 22, 2015 Increasing sophistication among enterprise buyers of ... purchasing in 2015, says Moravia CMO, ... study by market research firm Common Sense Advisory, 15 ... their translation and localization needs. "From a language industry ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... address remaining questions on Marketing ... Authorization Application, ... ) today announced that the Company recently presented to the,Committee ... the European Medicines Evaluation Agency (EMEA), regarding the,Marketing Authorization Application ...
... Infusional Chemotherapy ... -, NUTLEY, N.J., Jan. 24 Roche announced today ... have been,accepted for presentation at the 2008 Gastrointestinal Cancers Symposium ... presentations based on U.S. data offer additional knowledge,about Xeloda. Two ...
Cached Medicine Technology:IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 2IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 3IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 4IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 5Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium 2Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium 3
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... has released a new blog post explaining the importance of keeping ... costs of an auto insurance policy . , Clients who ... for their vehicle insurance policies. The safety a vehicle offers from ... Because of this, drivers should always carry a first aid kit ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... , , ST. PAUL, Minn., ... microscopic particle pollution like smoke and smog, as well as ... these airborne contaminants to experience shortness of breath, wheezing and ... irritation(1). According to AIRNow.gov(2), a government-developed index for reporting daily ...
... is providing valuable new clues into cancer,s deadliest behavior -- ... spreading throughout the body. Duke University biologist David ... of a single cell in the developing body of a ... one of its jobs is to connect the developing animal,s ...
... MP3 device -- just about every man, woman and child on the ... music, of the primal place it holds in the human imagination. ... the soul -- a frill that has to go when school budgets ... study shows that musicians -- trained to hear sounds embedded in a ...
... , Congressman Chaka Fattah (D-PA) releases the following statement on ... , WASHINGTON, Aug. 17 "We must not let the ... to take place it must include a public option. , ... they deliberate how they will get to their destination. Faced with a ...
... , , NEWINGTON, N.H. Aug. ... and hassle-free atmosphere have struck a chord with consumers, is being ... the fastest-growing private companies in America. , , ... Fitness finished number 471 on the lnc. 500, which ranks the ...
... , CHICAGO, Aug. 17 Presidential Towers, ... two bedroom apartment to the University of Illinois Medical Center (UIMC), ... care at the medical center. , , "Based ... felt that this was a great way to give back to ...
Cached Medicine News:Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3Health News:Cancer's break-in tools possibly identified at Duke 2Health News:Taking up music so you can hear 2Health News:Taking up music so you can hear 3Health News:Planet Fitness Soars to Inc. 500 2Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2
Streck Cytometry Sheath fluid is a ready-to-use, balanced isotonic solution for use on flow cytometers. It is packaged in a 20 liter Cubitainer, and offers a two-year shelf life....
Streck-T-Pack is specially designed for use on Coulter® Counter T Series instruments. Each convenient pack includes diluent, lysing agent and enzymatic cleanser. The shelf life is 18 months from ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
... A lytic reagent ... quantitative determination of hemoglobin ... Streck-Lysing Agent IIIA is ... on the Abbott CELL-DYN® ...
Medicine Products: